☰

BS Biotechna S.A.

Bringing preclinical nano-manufacturing under data control

Industry
Biotechnology (siRNA therapeutics and nano-drug delivery)
Headquarters
Kraków, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of BS Biotechna S.A.'s published strategy and is not endorsed by, or produced in cooperation with, BS Biotechna S.A.. Company website

Strategic priorities

BS Biotechna S.A. is a Kraków-based biotechnology company built around a proprietary nanoparticle platform that delivers two molecules with different mechanisms of action into a single drug, and a parallel siRNA (small interfering RNA) program that targets oncological genes previously described as undruggable. The company is running six preclinical programs in parallel — LU2020, WRM2023, KR2020, MEL2024, WA2021 and EL2024 — and the next milestone in the public record is the move into clinical-stage manufacturing.

Funding comes predominantly from Polish public instruments: project 2022/ABM/06/00005-00 from the Medical Research Agency (ABM) for personalised nucleic-acid medicine, plus FENG 'Ścieżka SMART' and NCBR (National Centre for Research and Development) grants totalling more than PLN 32 million. That shape of funding ties the company to ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) data integrity, FENG 'Zazielenienie' sustainability reporting and milestone documentation that can withstand public-audit review, and the company has been issuing structured requests for quotation (RFQ 7/2025 on real-time bioluminescence measurement of cell viability is one example) to bring the right instruments in.

The operational pivot is from bench-scale research to pilot-scale nano-manufacturing at the Kraków site on ul. Szlak 77. Nanoparticle synthesis is sensitive to small environmental fluctuations, the same line is expected to produce candidates for several programs in succession, and the equipment currently in use runs on proprietary vendor software. The route from a successful laboratory batch to a reproducible pilot batch is now the load-bearing question, and it depends on the data moving with the product.

Three working patterns set the agenda: an ontology of assays, specimens, results and instruments that lets the six programs be analysed together rather than one at a time; modular production architecture (MTP, or Module Type Package, the NAMUR open standard for vendor-independent automation modules) so a line built for one program can switch to another without a rebuild; and IT/OT (information technology / operational technology) convergence that brings the laboratory, the manufacturing floor and the grant-reporting system onto a single evidence chain.

Challenges we see

  • Operations Manufacturing

    Reproducing nanoparticle batches from bench to pilot scale

    Nanoparticle synthesis at BS Biotechna depends on precise mixing and stabilisation; small environmental fluctuations change the drug delivery profile. The same pilot line is expected to serve candidates from several programs in sequence, including LU2020, WRM2023, KR2020, MEL2024, WA2021 and EL2024.

    Where bench conditions are reproduced by hand, the population of variables a pilot batch has to track is larger than the eye can hold. Capturing process values at the bench and replaying them as setpoints at pilot scale makes the move from one scale to the next a question of data rather than of memory.

  • Digital Integration

    Unifying data across the six preclinical programs

    Spectrometers, cell-viability and bioluminescence testers, and synthesis units each carry their own vendor software. The same biological measurement is currently recorded in different structures across the six programs, and the comparison that pits candidates from one program against candidates from another happens by hand across those records.

    Once each instrument records into its own dialect, comparison between programs becomes a manual reconciliation step. An agreed shape for assay, specimen, result, instrument and lot lets the six programs be read against one model, so the cross-program comparison stops being a separate project.

  • Compliance Regulatory

    Producing ALCOA+-grade evidence for grant reporting

    Grant agreements with ABM (project 2022/ABM/06/00005-00 for personalised nucleic-acid medicine), NCBR and FENG require data that is Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring and Available — the ALCOA+ standard — and the company has been issuing structured requests for quotation (RFQ 7/2025 for real-time bioluminescence measurement of cell viability is one example) to bring the right instruments in.

    Where evidence is assembled from separate lab notebooks at reporting time, the link between an expenditure and the data it produced has to be reconstructed for each milestone. Capturing the evidence at the instrument with operator identity, timestamp and method version attached means the grant report reads off the record rather than off the file.

  • ESG Energy

    Tracking energy and waste against the FENG sustainability module

    The FENG 'Ścieżka SMART' program includes the 'Zazielenienie' (Greening of Enterprises) module, which requires monitoring and reduction of energy and waste footprints. Lab-heavy operations with ultra-low-temperature freezers and high-precision reactors account for the bulk of those footprints.

    When energy use is sampled manually each month, the picture the company reports is several steps removed from what is actually running. Continuous measurement at the equipment turns the sustainability obligation into something that can be steered during the year rather than audited after it.

  • Digital Security

    Protecting siRNA and nanoparticle intellectual property as R&D automation grows

    Proprietary siRNA sequences and nanoparticle structures are the company's core asset. As laboratory automation and remote collaboration with research partners increase, the OT (operational technology) layer connecting instruments carries more of that intellectual property than it did when records were kept on paper.

    Where lab instruments sit on a flat network, an attacker who reaches one has effectively reached the whole development programme. Segmenting the OT layer and applying identity-based access controls means the data path between an instrument and a remote collaborator is something the company chooses, not something that happens by default.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Capturing cell-viability and synthesis data as it is produced

    Real-time cell-viability and bioluminescence instruments produce results at the cadence of the experiment, but those results currently move into separate vendor systems and into Excel for further analysis. A measurement taken at 02:00 is several transcription steps away from the report that references it.

    Capturing instrument output through vendor-neutral protocols such as OPC UA (Open Platform Communications Unified Architecture, an industrial machine-to-machine communication standard) makes each result a data point in a shared model from the moment it is produced, with operator, method version and timestamp attached.

    • BS Biotechna Request for Quotation 7/2025, 14 January 2025
    • BS Biotechna R&D description, accessed January 2026

  2. Designing the pilot line so it can switch between programs

    The pilot line in Kraków is expected to produce candidates from several programs in sequence. Equipment selection made today will determine for the next decade whether switching from one program to another means a reconfiguration project or a routine changeover.

    Specifying MTP-conformant interfaces and OPC UA information models as procurement requirements brings the standards into the line from day one, so a new program arrives as a module to be loaded rather than a piece of hardware to be re-engineered.

    • BS Biotechna R&D description, accessed January 2026
    • FENG 'Ścieżka SMART' programme documentation, accessed January 2026

  3. Connecting grant-funded instruments to a single evidence record

    ABM, NCBR and FENG grants each require evidence that can be read independently. Instruments bought under different agreements currently write into different systems, and the milestone report pulls them together by hand.

    An instrument layer that writes results into a shared record with operator, instrument, method and timestamp means the milestone report is generated from the record, not assembled for it, and a single auditor-friendly view covers all three funding lines.

    • ABM Agreement 2022/ABM/06/00005-00
    • BS Biotechna Request for Quotation 13/2025, 17 January 2025

  4. Measuring energy and waste continuously at the equipment

    Freezers, incubators and synthesis units are the largest energy draws in the Kraków lab. Without continuous measurement, the FENG 'Zazielenienie' report is a manual roll-up of estimates, and deviations are noticed after the reporting period closes.

    Sensors on the equipment itself, with data carried over the same OPC UA infrastructure used for process values, put a per-asset energy and waste stream into the same dashboard as biological KPIs (key performance indicators), so reductions can be planned against measured baselines.

    • FENG 'Ścieżka SMART' programme documentation, accessed January 2026
    • BS Biotechna Kraków site description, accessed January 2026

  5. Reducing repetitive document work for grant and sustainability reporting

    Milestone reports, ABM and NCBR expenditure narratives, and the FENG sustainability module all draw on the same underlying data and are currently drafted by hand. Each reporting cycle repeats a large amount of assembly and cross-checking before a named reviewer ever sees the document.

    Narrow, reviewable agents can draft from the system record, check a document against its template and the funder's checklist, and find every controlled document a grant condition change affects, with a named person approving every output before it leaves the company.

    • BS Biotechna Request for Quotation 7/2025, 14 January 2025
    • FENG 'Ścieżka SMART' programme documentation, accessed January 2026

What we'd propose

  • Enterprise AI

    An ontology for the six preclinical programs

    We define assay, specimen, result, instrument and lot once, in a form both vendor instruments and internal synthesis records can write against, and load the six preclinical programs onto that single model.

    • Shared preclinical ontology

      One agreed shape for the data

      Define assay, specimen, result, instrument and lot as explicit entities with agreed relationships, so a query written once returns comparable answers across LU2020, WRM2023, KR2020, MEL2024, WA2021 and EL2024 instead of six dialects of the same table.

    • Instrument ingestion under OPC UA

      Vendor-neutral data capture

      Connect spectrometers, cell-viability testers and synthesis units through OPC UA, the industrial machine-to-machine communication standard, so process values leave the equipment in a documented form and land in the ontology with operator, method version and timestamp attached.

    • Cross-program analysis on the combined set

      Six programs read together

      Expose the combined data set through a query and retrieval layer so the cross-program comparison that today happens by hand across separate records can be run against one model, and new programs attach to it without a re-integration.

    • Cross-program comparison runs against one model instead of six parallel spreadsheets.
    • New instruments and new programs attach to the ontology rather than triggering another integration.
    • The combined data set becomes reusable for grant reporting as well as for science.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Modular pilot line with MTP interfaces

    We set the standards and information models for the pilot line in Kraków before procurement, so a program switch is a routine changeover rather than a reconfiguration project.

    • MTP-conformant process modules

      Vendor-independent automation

      Specify process modules against the MTP (Module Type Package) standard from NAMUR (the user association of process industries automation), so a new program can be loaded as a module rather than wired in by hand, and the next pilot asset joins the same architecture.

    • OPC UA information models for each unit operation

      Process values in a documented shape

      Define OPC UA information models for each unit operation on the line — synthesis, stabilisation, fill — so process values, setpoints and alarms move between modules without a custom interface per vendor.

    • Digital twin of the synthesis process

      Predicting batch outcome

      Build a digital twin of the nanoparticle synthesis process that predicts delivery profile and stability from historical runs, so candidate batches can be qualified against the model before they are run at pilot scale.

    • Switching programs becomes a module swap rather than a reconfiguration.
    • Vendor selection at procurement time is against the standard, not against the lowest quote.
    • Process knowledge gained on one program is carried forward to the next by the model, not by a single operator.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Connecting quality-control instruments to a grant-ready evidence record

    We integrate the laboratory instruments and their LIMS (Laboratory Information Management System) or ELN (Electronic Lab Notebook) so each result reaches the grant-milestone report as data with its own audit trail, removing the manual transcription step from the reporting path.

    • Instrument integration with full context

      Results captured at source

      Connect cell-viability, bioluminescence and spectroscopy instruments so each result carries instrument identity, method version and timestamp, instead of being read off a screen and retyped into a notebook or spreadsheet.

    • LIMS to evidence-record flow

      From sample to milestone report

      Map the LIMS or ELN sample and result records onto the grant-milestone evidence record so a milestone can be traced back to the specific run that produced each number, and a single auditor-friendly view spans ABM, NCBR and FENG lines.

    • ALCOA+ audit trail

      Evidence that holds up to audit

      Implement the ALCOA+ controls — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available — across the chain, so the evidence behind each milestone is generated by the instruments and held in a single auditable record.

    • Milestone reports are generated from the record rather than assembled for it.
    • Auditor questions are answered by the record itself, not by a reconstruction.
    • The same evidence chain serves ABM, NCBR and FENG reporting obligations.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Continuous energy and waste measurement for the FENG sustainability module

    We retrofit Kraków laboratory infrastructure with sensors carried over the same OPC UA infrastructure used for process values, so the FENG 'Zazielenienie' report reads off the same dashboard as biological KPIs.

    • Sensor layer on existing equipment

      Energy measured where it is used

      Add power and environmental sensors to freezers, incubators and synthesis units so energy and waste are measured at the equipment that produces them, with data carried over OPC UA alongside the process values.

    • Sustainability dashboard

      One view for the FENG report

      Build a dashboard that puts per-asset energy and waste next to the process KPIs the lab already monitors, so reductions can be planned against measured baselines rather than annual estimates.

    • Automated FENG reporting artefacts

      Evidence package for the funder

      Generate the reporting artefacts the FENG 'Zazielenienie' module requires from the same dashboard, so the submission is produced continuously and the company approaches each milestone with the evidence already in place.

    • The sustainability report is generated continuously, not assembled once a year.
    • Reductions are planned against measured baselines rather than rough estimates.
    • The same sensor layer is reusable when the next site is added or upgraded.

    We've done this before

    See how we do Digital Lab
  • Agents

    Narrow agents for grant and sustainability document work

    We deploy reviewable agents that take the repetitive part of grant and sustainability reporting: drafting milestone reports from the system record, checking a document against its template and the funder's checklist, and finding every controlled document a grant condition change affects. A named person at BS Biotechna approves every output before it leaves the company.

    • Drafting from the system record

      First drafts from real data

      Generate the first draft of an ABM, NCBR or FENG milestone report from the underlying system records, so the author edits and judges the document rather than assembling it from raw inputs.

    • Template and checklist completeness check

      Gaps found before review

      Check a document against the FENG 'Ścieżka SMART' template, the ABM milestone schedule, and the company's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change-impact search across the document set

      Which documents a grant change touches

      When a grant condition, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the scope of the update is known on day one.

    • Reporting cycles shorten because drafts arrive complete rather than half-assembled.
    • The scope of a grant-condition change is established by search rather than by recollection.
    • Every output is traceable to the system record it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what BS Biotechna S.A.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 25 → 80
Spectrometers, cell-viability testers and synthesis units run on proprietary vendor software, and KPI tracking happens in Excel. The same measurement currently exists in several structures across the six preclinical programs, and the public RFQs (requests for quotation) issued in early 2025 are a signal that this state is acknowledged.
Process automation 30 → 75
Bench-scale work is supported by instruments, and the move to pilot-scale nano-manufacturing is now the topic of structured procurement. Process values from one scale are not yet carried forward to the next by a system, so the move currently depends on operator memory.
Regulatory reporting 35 → 88
More than PLN 32 million in grants from ABM, NCBR and FENG carry ALCOA+ and FENG 'Ścieżka SMART' reporting conditions. The evidence behind each milestone is being assembled for the report rather than generated by the instruments, which leaves the company with room to lift current maturity substantially.
Cybersecurity posture 22 → 70
The OT layer is connected enough to support automated R&D but is not yet segmented under IEC 62443 or governed by identity-based access controls, so the company's most valuable intellectual property is reachable through a relatively flat network.
Sustainability tracking 18 → 65
FENG 'Zazielenienie' obligations exist on paper but the energy and waste measurements behind them are sampled manually. Continuous measurement at the equipment is the obvious next step and has not yet been deployed.
Predictive analytics 12 → 60
Historical experimental data exists but lives in vendor systems. Cross-program comparison across the six programs is done by hand, and a digital twin of the nanoparticle synthesis process has not yet been built. The room to grow is real but depends on the ontology work above.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with BS Biotechna S.A., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].